H2 Receptor Blockers and Antacids

Introduction/Overview

Gastro‑oesophageal reflux disease (GERD), peptic ulcer disease (PUD), and Zollinger–Ellison syndrome represent common disorders of gastric acid secretion that impose a significant burden on patients and health‑care systems worldwide. The therapeutic armamentarium for acid‑related disorders includes several pharmacologic classes, among which histamine‑2 (H2) receptor blockers and antacids occupy a central position. These agents act through distinct mechanisms yet converge on the same clinical endpoint of reducing gastric acidity, thereby facilitating mucosal healing and alleviating symptoms. A comprehensive understanding of their pharmacology is essential for clinicians and pharmacists in order to optimize therapy, anticipate adverse effects, and navigate drug interactions.

Learning objectives

• Describe the chemical and pharmacologic classification of H2 receptor blockers and antacids.
• Explain the mechanisms of action at molecular, cellular, and systemic levels.
• Summarize the pharmacokinetic properties that inform dosing and therapeutic monitoring.
• Identify approved indications, off‑label uses, and contraindications for both drug classes.
• Recognize major adverse events, drug interactions, and special population considerations.

Classification

H2 Receptor Blockers

H2 receptor blockers, also known as histamine‑2 antagonists, belong to the class of competitive inhibitors of histamine binding at the H2 subtype of the histamine receptor located on parietal cells. They are structurally related to the histamine molecule and share a central imidazole ring critical for receptor affinity. The major agents in clinical use include ranitidine, famotidine, cimetidine, nizatidine, and the newer generation drug, famotidine, which has gained preference due to a superior safety profile.

Antacids

Antacids are a heterogeneous group of agents that neutralize gastric acid by direct chemical reaction. They are broadly classified according to their active components: aluminum salts (aluminum hydroxide), magnesium salts (magnesium hydroxide, magnesium oxide), calcium salts (calcium carbonate), and combinations thereof. Some antacids contain additional buffering agents such as bicarbonate or employ enteric coatings to limit dissolution in the acidic stomach environment.

Mechanism of Action

H2 Receptor Blockers

Parietal cells, located in the gastric mucosa, secrete hydrochloric acid via the H+/K+ ATPase pump. Histamine binding to H2 receptors stimulates adenylate cyclase, elevating intracellular cyclic AMP and promoting proton secretion. H2 receptor blockers competitively inhibit histamine from binding to these receptors, thereby attenuating the downstream signaling cascade that culminates in acid secretion. The blockade is reversible and dose‑dependent, with maximal inhibition occurring at therapeutic plasma concentrations. Additionally, H2 antagonists exhibit partial antagonism of acetylcholine and gastrin‑mediated stimulation, contributing to a broader suppression of acid output.

Antacids

Antacids act through a direct physical interaction with gastric acid. In the acidic milieu of the stomach, metal cations (e.g., Al3+, Mg2+, Ca2+) react with HCl to form insoluble salts, releasing hydroxide ions that elevate gastric pH. The neutralization reaction is rapid and short‑lasting, typically lasting 2–4 hours. Importantly, antacids do not influence the regulatory mechanisms of acid secretion; rather, they provide symptomatic relief by buffering the acidity that has already been produced.

Molecular and Cellular Considerations

The affinity of H2 antagonists for the receptor is largely determined by the imidazole ring’s ability to form hydrogen bonds with the receptor’s binding pocket. Modifications to the side chain can influence lipophilicity, thereby affecting absorption and distribution. In contrast, antacid efficacy is predominantly governed by the solubility of the metal hydroxide in the gastric fluid and the kinetics of the neutralization reaction. The buffering capacity of antacids is also influenced by the presence of bicarbonate, which can rapidly release CO2, leading to belching.

Pharmacokinetics

H2 Receptor Blockers

Absorption is generally rapid and complete when taken orally, although the presence of food may delay peak plasma concentrations. Distribution is extensive, with plasma protein binding ranging from 20% to 70% depending on the specific agent. Hepatic metabolism predominates for most H2 blockers, involving cytochrome P450 enzymes (e.g., CYP2D6, CYP3A4). Excretion occurs via both renal and fecal routes; the balance shifts toward renal elimination for hydrophilic metabolites while lipophilic compounds may undergo biliary excretion. Half‑lives vary considerably: cimetidine has a short half‑life (~2 hours), whereas famotidine is longer (~2–3 hours) and can be extended in renal impairment. Dose adjustments are recommended in patients with significant renal dysfunction to avoid accumulation.

Antacids

Antacids are not absorbed to a clinically significant extent; thus, systemic exposure is minimal. Their pharmacokinetic profile is therefore largely irrelevant for therapeutic efficacy, except insofar as it influences the duration of gastric pH elevation. The rate of gastric emptying and the presence of other oral substances can affect the dissolution and neutralization kinetics, thereby modulating the duration of symptom relief. Because absorption is negligible, antacids are free from concerns regarding drug–drug interactions that involve hepatic metabolism.

Therapeutic Uses/Clinical Applications

Approved Indications

H2 receptor blockers are indicated for the following conditions:

• Gastro‑oesophageal reflux disease (GERD) – both erosive and non‑erosive forms.
• Peptic ulcer disease (PUD) – as monotherapy or in combination with antibiotics for Helicobacter pylori eradication.
• Zollinger–Ellison syndrome – to suppress gastrin‑driven hyperacidity.
• Prevention of stress‑related mucosal damage in critically ill patients.

Antacids are commonly used for acute symptom relief in:

• GERD – particularly post‑prandial heartburn.
• Acute dyspepsia and epigastric burning.
• Post‑operative nausea and vomiting when associated with acid secretion.

Off‑Label and Emerging Uses

H2 blockers have been employed off‑label for the treatment of atopic dermatitis, chronic urticaria, and certain neuropsychiatric conditions, though evidence remains limited. In the context of COVID‑19, transient acid suppression has been examined as a potential adjunct for symptom control, but robust data are lacking. Antacids have occasionally been used to mitigate drug‑induced gastric irritation, such as that caused by NSAIDs or bisphosphonates; however, their efficacy in preventing ulceration is modest compared with proton pump inhibitors (PPIs).

Adverse Effects

H2 Receptor Blockers

Common side effects include headache, dizziness, constipation, and diarrhea. Rare but serious events reported include hepatotoxicity, interstitial nephritis, and thrombocytopenia. Certain H2 blockers, particularly cimetidine, have been associated with a higher incidence of drug interactions due to extensive inhibition of CYP450 enzymes, which can lead to altered plasma levels of concomitant medications. A black‑box warning is not currently issued for H2 antagonists; however, caution is advised when prescribing in individuals with hepatic or renal impairment.

Antacids

Antacids may cause gastrointestinal disturbances such as bloating, flatulence, constipation (aluminum‑based formulations), or diarrhea (magnesium‑based formulations). Long‑term use of aluminum salts has been associated with hypophosphatemia and osteomalacia, particularly in patients with impaired renal function. Calcium‑carbonate antacids may contribute to hypercalcemia in susceptible populations. Antacids containing magnesium may precipitate hypermagnesemia in patients with renal insufficiency. Overuse of antacids can also alter the absorption of concomitant medications, for example, by binding to drug molecules and forming insoluble complexes.

Drug Interactions

H2 Receptor Blockers

Metabolic inhibition by cimetidine and, to a lesser extent, ranitidine and famotidine, can increase plasma concentrations of drugs metabolized by CYP3A4, CYP2D6, and CYP1A2. Notable interactions include increased levels of theophylline, diazepam, and carbamazepine. Moreover, H2 blockers may interfere with the absorption of drugs requiring an acidic environment, such as ketoconazole, atazanavir, and rifampin. In patients taking anticoagulants like warfarin, H2 blockade can modestly increase INR levels by affecting vitamin K absorption.

Antacids

Given their minimal systemic absorption, antacids exert drug interactions primarily through gastric pH alteration. Acid‑dependent drugs (e.g., ketoconazole, atazanavir, rifampin) may exhibit reduced bioavailability when antacids are co‑administered. Antacids containing calcium or magnesium can precipitate with tetracyclines and fluoroquinolones, diminishing their absorption. Timing recommendations typically advise separating antacid administration from these medications by at least 2 hours.

Special Considerations

Pregnancy and Lactation

H2 blockers are classified as pregnancy category B or C, depending on the specific agent, and are generally considered safe when indicated, though data are limited. Cimetidine has been used in pregnancy for the treatment of severe GERD without definitive evidence of teratogenicity. Antacids are widely used during pregnancy, especially in first‑trimester nausea, and are regarded as safe; however, aluminum‑based formulations should be avoided in patients with renal impairment.

Pediatric and Geriatric Populations

In children, H2 blockers are commonly prescribed for GERD and PUD, with dosing adjusted for weight. The safety profile in pediatric patients is favourable, though rare cases of hepatotoxicity have been reported. In the elderly, age‑related decline in renal function may necessitate dose reduction for agents primarily cleared renally. Polypharmacy increases the risk of drug interactions, making careful medication reconciliation essential.

Renal and Hepatic Impairment

Renal impairment may prolong the half‑life of H2 blockers such as famotidine, warranting dose adjustment or extended dosing intervals. Cimetidine, which is heavily metabolized hepatically, may accumulate in hepatic dysfunction, leading to increased risk of hepatotoxicity. Antacids containing magnesium should be used cautiously in patients with chronic kidney disease to avoid hypermagnesemia. Aluminum‑based antacids may be contraindicated in patients with reduced glomerular filtration rate due to the risk of systemic aluminum accumulation.

Summary/Key Points

• H2 receptor blockers competitively inhibit histamine binding at parietal‑cell H2 receptors, reducing gastric acid secretion.
• Antacids neutralize gastric acid through direct chemical reaction, offering rapid but short‑lasting symptom relief.
• H2 blockers are metabolized hepatically and eliminated renally; dose adjustments are required in renal/hepatic impairment.
• Antacids are minimally absorbed; their primary consideration involves gastric pH alteration and potential interference with drug absorption.
• Common adverse events include headache, dizziness, and gastrointestinal disturbances; rare events involve hepatotoxicity and electrolyte imbalances.
• Drug interactions are most notable with cimetidine and other H2 blockers affecting CYP450 enzymes; antacids can interfere with absorption of acid‑dependent drugs.
• Special populations—pregnancy, pediatrics, geriatric, renal/hepatic impairment—require individualized dosing and monitoring.
• Clinical decision‑making should weigh the advantages of sustained acid suppression with H2 blockers against the rapid pH elevation provided by antacids, tailoring therapy to patient needs and comorbidities.

References

1. Hall JE, Hall ME. Guyton and Hall Textbook of Medical Physiology. 14th ed. Philadelphia: Elsevier; 2021.
2. Barrett KE, Barman SM, Brooks HL, Yuan JX. Ganong's Review of Medical Physiology. 26th ed. New York: McGraw-Hill Education; 2019.
3. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
4. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
5. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
6. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
7. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
8. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.